Autopsy report · NCT01320501

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

“Difficulty in enrolling patients”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 5 months after it had already started.
• Suspended: paused, and may or may not restart.
• 100 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 4

Sponsor

National Guard Health Affairs

Sponsor type

Government (non-US federal)

Conditions

Non-small Cell Lung Cancer Metastatic

Interventions

Erlotinib

Participants

100 (planned, not actual)

Sites

1

Countries

Saudi Arabia

Trials that died the same way

• Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation
  “Difficulty enrolling patients” (99% match in meaning)
• Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)
  “difficulty of enrolling patients” (98% match in meaning)
• Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases
  “Difficulty in enrolling new patients” (92% match in meaning)
• Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
  “Unable to enroll appropriate patients” (88% match in meaning)
• Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients
  “Difficulty in with enrollment of patient” (88% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.